SCHEMBL2566819

SCHEMBL2566819

CC(C)(CNc1ccc(-c2ccc3[nH]nc(N)c3c2)nn1)c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 5/20 0.44
JAK2 O60674 12/20 0.43
JAK3 P52333 5/20 0.40
AURKB Q96GD4 5/20 0.40
CDK2 P24941 5/20 0.40
DAPK3 O43293 4/20 0.40
ROCK2 O75116 4/20 0.40
CDK1 P06493 4/20 0.40
MARK3 P27448 4/20 0.40
CDK5 Q00535 4/20 0.40
PRKCD Q05655 4/20 0.40
ROCK1 Q13464 4/20 0.40
DYRK1A Q13627 4/20 0.40
PRKD2 Q9BZL6 4/20 0.40
GSK3A P49840 3/20 0.40
PLK4 O00444 3/20 0.40
DYRK3 O43781 3/20 0.40
MAP4K4 O95819 3/20 0.40
CLK2 P49760 3/20 0.40
PKN2 Q16513 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12287444 0.93 ABL1 (0.47) JAK3AURKBCDK2ROCK1RPS6KB1
SCHEMBL2559686 0.92 JAK2 (0.38) CDC7JAK2JAK3AURKBCDK2
SCHEMBL19422107 0.91 CDC7 (0.45) CDC7JAK2JAK3AURKBCDK2
SCHEMBL12289987 0.91 JAK2 (0.44) CDC7JAK2JAK3AURKBCDK2
SCHEMBL21170075 0.90 PSEN1 (0.39) CDC7JAK3CDK2DAPK3ROCK2
SCHEMBL12286590 0.90 JAK2 (0.46) CDC7JAK2JAK3AURKBCDK2
SCHEMBL2566241 0.89 JAK2 (0.43) CDC7JAK2JAK3AURKBCDK2
SCHEMBL12286539 0.89 PSEN1 (0.36) CDC7JAK2JAK3CDK2DAPK3
SCHEMBL12287422 0.89 CDC7 (0.46) CDC7JAK2JAK3AURKBCDK2
SCHEMBL12287338 0.89 NTRK1 (0.44) CDC7JAK2JAK3CDK2DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9604965-B2 Substituted pyridazines as skeletal muscle modulators CYTOKINETICS, INC. (US) 2017-03-28 US claimed
US-20150322018-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE ASHCRAFT LUKE W (US) 2015-11-12 US claimed
CN-107266419-B Certain amino-pyridazines, compositions thereof, and methods of use thereof 赛特凯恩蒂克公司 2021-05-11 CN disclosed
EP-3127541-B1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS INC (US) 2019-07-17 EP disclosed
EP-3127541-B1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS INC (US) 2019-07-17 EP disclosed
US-10076519-B2 Substituted pyridazines as skeletal muscle modulators CYTOKINETICS, INC. (US) 2018-09-18 US disclosed
US-20170281621-A1 SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS CYTOKINETICS INC (US) 2017-10-05 US disclosed
US-20170281621-A1 SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS CYTOKINETICS INC (US) 2017-10-05 US disclosed
US-20170281621-A1 SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS CYTOKINETICS INC (US) 2017-10-05 US disclosed
US-9604965-B2 Substituted pyridazines as skeletal muscle modulators CYTOKINETICS, INC. (US) 2017-03-28 US disclosed
US-9604965-B2 Substituted pyridazines as skeletal muscle modulators CYTOKINETICS, INC. (US) 2017-03-28 US disclosed
US-8969346-B2 Amino-pyridazine skeletal muscle modulators CYTOKINETICS, INC. (US) 2015-03-03 US disclosed
US-8969346-B2 Amino-pyridazine skeletal muscle modulators CYTOKINETICS, INC. (US) 2015-03-03 US disclosed
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS, INC. 2013-06-06 US disclosed
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS, INC. 2013-06-06 US disclosed
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS, INC. 2013-06-06 US disclosed
CN-103002897-A Certain amino-pyridazines, compositions thereof, and methods of use thereof CYTOKINETICS INC 2013-03-27 CN disclosed
EP-2563365-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE Cytokinetics, Inc. (US) 2013-03-06 EP disclosed
WO-2011133882-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS, INC. (US) 2011-10-27 WO disclosed
WO-2011133882-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS, INC. (US) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281621-A1 SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS MUSK, PYGM, GYS1 CDC7 4645/4885JAK2 704/4885JAK3 1060/4885
US-10076519-B2 Substituted pyridazines as skeletal muscle modulators MUSK, PYGM, GYS1 CDC7 4645/4885JAK2 704/4885JAK3 1060/4885
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE SLC7A1, F12, C5 CDC7 3755/4885JAK2 40/4885JAK3 89/4885
US-20150322018-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE SLC7A1, F12, C5 CDC7 3691/4885JAK2 41/4885JAK3 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.